학술논문
A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers
Document Type
Article
Author
Source
In: Clinical Cancer Research . (Clinical Cancer Research, 1 January 2022, 28(1):71-83)
Subject
Language
English
ISSN
15573265
10780432
10780432